← Leaderboards
Edward P Garvey
Mycovia Pharmaceuticals, Inc.
$985,000
Attributed
$985,000
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $373K · FY2012–16$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$985,000 · 2
By mechanism
R33$710,000 · 1
R21$275,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Efficacy Testing”
- Lawrence Corey · Fred Hutchinson Cancer Center$545,833,883
- Barton F Haynes · Duke University$498,883,674
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$449,028,696
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$350,577,345
- Peter B. Gilbert · Fred Hutchinson Cancer Center$210,957,667
- Dennis R. Burton · Scripps Research Institute$199,946,411
Research focus
Efficacy TestingEnzyme Inhibitor DrugsAcuteEffective TherapyAntifungal AgentsBaseBiologicalAntifungal TherapyArthrodermataceaeCanis FamiliarisClinical EfficacyAzolesClinical ResearchClinical TrialsCoccidioidesCoccidioides ImmitisBreathingCoccidioidomycosisCollectionCandidiasisCytochrome P450DoseDrug KineticsEnzymes
Grant awards (5)
Optimized CYP51 Inhibitors for the Oral Treatment of CNS Coccidioides Infections$95,000
R33 · FY2016 · AI · contact PI
Optimized CYP51 Inhibitors for the Oral Treatment of CNS Coccidioides Infections$373,000
R33 · FY2015 · AI · contact PI
Optimized CYP51 Inhibitors for the Oral Treatment of CNS Coccidioides Infections$242,000
R33 · FY2014 · AI · contact PI
Optimized CYP51 Inhibitors for the Oral Treatment of CNS Coccidioides Infections$145,000
R21 · FY2013 · AI · contact PI
Optimized CYP51 Inhibitors for the Oral Treatment of CNS Coccidioides Infections$130,000
R21 · FY2012 · AI · contact PI